The Illumina Inc. (ILMN) Given a $142.00 Price Target at Barclays PLC

The Illumina Inc. (ILMN) Given a $142.00 Price Target at Barclays PLC

Barclays PLC set a $142.00 target price on Illumina Inc. (NASDAQ:ILMN) in a research report sent to investors on Tuesday. The brokerage currently has a a hold rating on the life sciences company’s stock.

Other equities analysts also recently issued reports about the company. Citigroup Inc. downgraded Illumina from a buy rating to a neutral rating and reduced their price objective for the stock from $190.00 to $140.00 in a research report on Tuesday. Janney Montgomery Scott downgraded Illumina from a neutral rating to a sell rating and reduced their price objective for the stock from $155.00 to $125.00 in a research report on Tuesday. Cantor Fitzgerald reduced their price objective on Illumina from $165.00 to $155.00 and set a hold rating for the company in a research report on Tuesday. JPMorgan Chase & Co. boosted their price objective on Illumina from $185.00 to $200.00 and gave the stock an overweight rating in a research report on Wednesday, July 27th. Finally, Mizuho boosted their price objective on Illumina from $138.00 to $148.00 and gave the stock a neutral rating in a research report on Wednesday, July 27th. Two analysts have rated the stock with a sell rating, fifteen have given a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. Illumina has a consensus rating of Hold and an average target price of $159.24.

Illumina (NASDAQ:ILMN) traded down 1.60% during midday trading on Tuesday, reaching $136.76. The company had a trading volume of 1,225,690 shares. The company’s 50 day moving average is $174.01 and its 200-day moving average is $156.43. Illumina has a 52-week low of $127.10 and a 52-week high of $196.47. The company has a market capitalization of $20.05 billion, a P/E ratio of 46.84 and a beta of 0.47.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Tuesday, July 26th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.73 by $0.13. The business earned $600 million during the quarter, compared to the consensus estimate of $31.91 million. Illumina had a return on equity of 23.69% and a net margin of 18.73%. The business’s revenue was up 11.3% on a year-over-year basis. During the same period in the previous year, the firm posted $0.80 earnings per share. Equities analysts expect that Illumina will post $3.53 earnings per share for the current fiscal year.

In other Illumina news, Director Daniel Bradbury sold 600 shares of the company’s stock in a transaction dated Friday, October 7th. The shares were sold at an average price of $184.36, for a total transaction of $110,616.00. Following the completion of the sale, the director now directly owns 17,065 shares in the company, valued at $3,146,103.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Roy A. Whitfield sold 4,000 shares of the company’s stock in a transaction dated Friday, August 12th. The shares were sold at an average price of $167.22, for a total transaction of $668,880.00. Following the sale, the director now owns 6,853 shares of the company’s stock, valued at $1,145,958.66. The disclosure for this sale can be found here. Company insiders own 1.60% of the company’s stock.

Large investors have recently added to or reduced their stakes in the stock. Physicians Financial Services Inc. boosted its stake in Illumina by 2,121.2% in the second quarter. Physicians Financial Services Inc. now owns 733 shares of the life sciences company’s stock worth $103,000 after buying an additional 700 shares during the period. Northwestern Mutual Wealth Management Co. boosted its stake in Illumina by 25.0% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 789 shares of the life sciences company’s stock valued at $110,000 after buying an additional 158 shares during the last quarter. Fuller & Thaler Asset Management Inc. bought a new stake in Illumina during the second quarter valued at $112,000. Ropes Wealth Advisors LLC boosted its stake in Illumina by 72.6% in the second quarter. Ropes Wealth Advisors LLC now owns 863 shares of the life sciences company’s stock valued at $121,000 after buying an additional 363 shares during the last quarter. Finally, Checchi Capital Advisers LLC boosted its stake in Illumina by 2.4% in the second quarter. Checchi Capital Advisers LLC now owns 958 shares of the life sciences company’s stock valued at $134,000 after buying an additional 22 shares during the last quarter. Institutional investors own 95.22% of the company’s stock.

About Illumina

Related posts

Leave a Comment